Clinical breast cancer
Positive Immunoreactivities of TM9SF1 and EBAG9 are Associated With Poor Prognosis in Patients With Triple-Negative Breast Cancer.
Keiichi Kinowaki, Toshihiko Takeiwa, Kazuhiro Ikeda, Akihiro Fujimoto, Kotaro Azuma, Kuniko Horie, Hidetaka Kawabata, Satoshi Inoue
Published: 202510.1016/j.clbc.2025.09.007
Abstract
INTRODUCTION: TNBC demonstrates poor prognosis compared to other breast cancer types due to the lack of targetable molecular markers. Protein expression of EBAG9 has been associated with unfavorable prognosis in patients with various malignancies. Re…
Preview only. Read the full abstract at the source